menuclose
HOME > Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR‑mutant lung cancer with HIF‑1α/TGF‑α expression
お知らせ

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR‑mutant lung cancer with HIF‑1α/TGF‑α expression

このお知らせには詳しい内容はありません
すべて 月別

Snapshot of OKADAI BIOBANK